Krystal Biotech Statistics
Total Valuation
Krystal Biotech has a market cap or net worth of $7.14 billion. The enterprise value is $6.29 billion.
Important Dates
The next estimated earnings date is Wednesday, February 18, 2026, before market open.
| Earnings Date | Feb 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Krystal Biotech has 29.00 million shares outstanding. The number of shares has increased by 1.34% in one year.
| Current Share Class | 29.00M |
| Shares Outstanding | 29.00M |
| Shares Change (YoY) | +1.34% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 11.30% |
| Owned by Institutions (%) | 88.61% |
| Float | 22.88M |
Valuation Ratios
The trailing PE ratio is 36.98 and the forward PE ratio is 34.87. Krystal Biotech's PEG ratio is 0.59.
| PE Ratio | 36.98 |
| Forward PE | 34.87 |
| PS Ratio | 19.05 |
| Forward PS | 13.78 |
| PB Ratio | 6.28 |
| P/TBV Ratio | 6.28 |
| P/FCF Ratio | 43.14 |
| P/OCF Ratio | 40.55 |
| PEG Ratio | 0.59 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 39.39, with an EV/FCF ratio of 37.98.
| EV / Earnings | 31.62 |
| EV / Sales | 16.85 |
| EV / EBITDA | 39.39 |
| EV / EBIT | 39.72 |
| EV / FCF | 37.98 |
Financial Position
The company has a current ratio of 10.14, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.14 |
| Quick Ratio | 9.43 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.06 |
| Debt / FCF | 0.06 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 19.66% and return on invested capital (ROIC) is 9.70%.
| Return on Equity (ROE) | 19.66% |
| Return on Assets (ROA) | 8.91% |
| Return on Invested Capital (ROIC) | 9.70% |
| Return on Capital Employed (ROCE) | 13.78% |
| Revenue Per Employee | $1.36M |
| Profits Per Employee | $723,309 |
| Employee Count | 275 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 0.76 |
Taxes
| Income Tax | -11.96M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +58.12% in the last 52 weeks. The beta is 0.46, so Krystal Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | +58.12% |
| 50-Day Moving Average | 222.04 |
| 200-Day Moving Average | 171.32 |
| Relative Strength Index (RSI) | 60.11 |
| Average Volume (20 Days) | 285,572 |
Short Selling Information
The latest short interest is 2.72 million, so 9.38% of the outstanding shares have been sold short.
| Short Interest | 2.72M |
| Short Previous Month | 2.87M |
| Short % of Shares Out | 9.38% |
| Short % of Float | 11.89% |
| Short Ratio (days to cover) | 9.30 |
Income Statement
In the last 12 months, Krystal Biotech had revenue of $373.16 million and earned $198.91 million in profits. Earnings per share was $6.66.
| Revenue | 373.16M |
| Gross Profit | 351.76M |
| Operating Income | 158.35M |
| Pretax Income | 186.95M |
| Net Income | 198.91M |
| EBITDA | 159.67M |
| EBIT | 158.35M |
| Earnings Per Share (EPS) | $6.66 |
Full Income StatementBalance Sheet
The company has $731.07 million in cash and $9.51 million in debt, with a net cash position of $854.67 million or $29.47 per share.
| Cash & Cash Equivalents | 731.07M |
| Total Debt | 9.51M |
| Net Cash | 854.67M |
| Net Cash Per Share | $29.47 |
| Equity (Book Value) | 1.14B |
| Book Value Per Share | 39.26 |
| Working Capital | 834.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $176.20 million and capital expenditures -$10.61 million, giving a free cash flow of $165.59 million.
| Operating Cash Flow | 176.20M |
| Capital Expenditures | -10.61M |
| Free Cash Flow | 165.59M |
| FCF Per Share | $5.71 |
Full Cash Flow StatementMargins
Gross margin is 94.26%, with operating and profit margins of 42.43% and 53.30%.
| Gross Margin | 94.26% |
| Operating Margin | 42.43% |
| Pretax Margin | 50.10% |
| Profit Margin | 53.30% |
| EBITDA Margin | 42.79% |
| EBIT Margin | 42.43% |
| FCF Margin | 44.37% |
Dividends & Yields
Krystal Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.34% |
| Shareholder Yield | -1.34% |
| Earnings Yield | 2.78% |
| FCF Yield | 2.32% |
Dividend DetailsAnalyst Forecast
The average price target for Krystal Biotech is $226.56, which is -8.04% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $226.56 |
| Price Target Difference | -8.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 29.54% |
| EPS Growth Forecast (5Y) | 52.23% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Krystal Biotech has an Altman Z-Score of 28.67 and a Piotroski F-Score of 6.
| Altman Z-Score | 28.67 |
| Piotroski F-Score | 6 |
